DAX®12.542,44-4,37%TecDAX®2.995,45-3,93%Dow Jones 3027.147,70-1,84%Nasdaq 10010.980,22+0,40%

DGAP-Adhoc: Epigenomics AG successfully completes capital increase

| Quelle: Dow Jones Newsw... | Lesedauer etwa 4 min. | Text vorlesen Stop Pause Fortsetzen

DGAP-Ad-hoc: Epigenomics AG / Key word(s): Capital Increase/Corporate Action
Epigenomics AG successfully completes capital increase

07-Nov-2019 / 23:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


*Epigenomics AG successfully completes capital increase*

*Berlin, 7 November 2019* - Epigenomics AG (Frankfurt Prime Standard: ECX,
OTCQX: EPGNY) has placed the new shares from the capital increase resolved
on October 17, 2019 in an amount of EUR 7,506,152.00*. *Accordingly, the
Company's share capital will be increased from currently EUR 36,021,540.00
by EUR 7,506,152.00 to EUR 43,527,692.00 by 7,506,152 new registered shares
of the Company against cash contributions.

The shares from the private placement were allocated to multiple investors,
including, in particular, institutional investors from the U.S.A. and

The gross proceeds from the capital increase amount to approximately EUR 8.3

The capital increase needs to be registered in the commercial register,
which the Executive Board will apply for shortly. The inclusion of the new
shares under the Company's existing listing (ISIN DE000A11QW50) is currently
expected to take place at or around November 13, 2019.

*Company *
Epigenomics AG
Genest Street 5
10829 BerlinTel
+49 (0) 30 24345 0
Fax +49 (0) 30 24345 555
E-mail: ir@epigenomics.com

*Investor Relations*
IR.on AG
Frederic Hilke, Fabian Kirchmann
Phone +49 221 9140 970
E-mail: ir@epigenomics.com

*Important Notice*

This publication does not constitute or form part of, and should not be
construed as an offer or an invitation to sell, or issue or the solicitation
of any offer to buy or subscribe for, any securities. The shares will be
solely offered on the basis of the published subscription offer and the
prospectus approved by the German Federal Financial Supervisory Authority
(BaFin - Bundesanstalt für Finanzdienstleistungsaufsicht). The prospectus
was published on the Company's website at www.epigenomics.com after approval
by BaFin on October 18, 2019. The subscription offer was published on
October 21, 2019.

This publication does, in particular, not constitute an offer to sell or a
solicitation of an offer to purchase any securities in the United States.
The securities referred to herein have not been and will not be registered
under the U.S. Securities Act of 1933, as amended (the "Securities Act") or
the laws of any state within the U.S., and may not be offered or sold in the
United States or to or for the account or benefit of U.S. persons, except
that the offered shares may be offered or sold to qualified institutional
buyers in reliance on certain exemptions from the registration requirements
of the Securities Act and applicable state securities laws. This publication
and the information contained herein may not be distributed or sent into the
United States, or in any other jurisdiction in which offers or sales of the
securities described herein would be prohibited by applicable laws, and
should not be distributed to United States persons or by way of publications
with a general circulation in the United States. No public offering of the
shares is being made in the United States. Subject to certain exceptions,
the securities referred to herein may not be offered or sold in Australia,
Canada or Japan or to, or for the account or benefit of, any national,
resident or citizen of Australia, Canada or Japan. The securities referred
to herein have not been and will not be registered under the applicable
securities laws of Australia, Canada or Japan.

*Forward-Looking Statements*

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any expected
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events or

07-Nov-2019 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A11QW50
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
EQS News ID: 907885

End of Announcement DGAP News Service

907885 07-Nov-2019 CET/CEST

(END) Dow Jones Newswires

November 07, 2019 17:36 ET ( 22:36 GMT)

Das könnte Sie auch interessieren



Aktuelle Videos

HSBC Trading TV



Börsen & Märkte


zur Mediathek

Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Der Bundestag hat dem Antrag der Grünen nach einem Tempolimit auf Autobahnen eine Absage erteilt. Wären Sie dafür gewesen?
Jetzt abstimmen!
Alle Umfragen ansehen